Form 4: Curis Inc. CFO Diantha Duvall Reports Stock Option Grant
SEC Form 4 Filing
Diantha Duvall, CFO of Curis Inc., reports the grant of a stock option for 135,000 shares of common stock at an exercise price of $3.13, vesting quarterly until January 2029.
Summary
- Diantha Duvall, the CFO of Curis Inc., filed a Form 4 disclosing a transaction related to derivative securities.
- On May 20, 2025, Duvall was granted an employee stock option to purchase 135,000 shares of Curis Inc. common stock at an exercise price of $3.13 per share.
- The option grant was contingent upon shareholder approval of Amendment No. 1 to the Fifth Amended and Restated 2010 Stock Incentive Plan, which was obtained on May 20, 2025.
- The options vest as to 25% of the original shares on January 28, 2026, and then an additional 6.25% each quarter until January 28, 2029.
- The expiration date for the options is January 27, 2035.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating confidence in the company's future. The sentiment is neutral to positive.
Positives
- The grant of stock options to the CFO aligns her interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CFO.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the options.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- The size of the grant and the vesting schedule are typical for a CFO at a company of Curis's size and stage.
- Comparable companies such as XOMA Corporation and Agenus Inc. also utilize stock options as part of their executive compensation plans.
Stakeholder Impact
- Shareholders may view the option grant as a positive incentive for the CFO to drive company performance.
- Employees may see the option grant as a sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| January 28, 2025 | Board of Directors approved the option grant contingent upon shareholder approval. |
| May 20, 2025 | Shareholders approved Amendment No. 1 to the Fifth Amended and Restated 2010 Stock Incentive Plan, making the option grant effective. |
| May 20, 2025 | Date of the stock option grant. |
| January 28, 2026 | First vesting date for 25% of the option shares. |
| January 28, 2029 | Final vesting date for the option shares. |
| January 27, 2035 | Expiration date of the stock option. |
Keywords
stock option, Form 4, Diantha Duvall, Curis Inc., CFO, equity, CRIS
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.